PARATEK PHARMACEUTICALS INC's ticker is PRTK and the CUSIP is 699374302. A total of 104 filers reported holding PARATEK PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.93 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $121,000 | -65.2% | 30,340 | -55.3% | 0.01% | -68.2% |
| Q4 2018 | $348,000 | -63.4% | 67,918 | -7.1% | 0.02% | -42.1% |
| Q1 2018 | $950,000 | +220.9% | 73,137 | +342.3% | 0.04% | +192.3% |
| Q4 2017 | $296,000 | -18.7% | 16,537 | +13.8% | 0.01% | -31.6% |
| Q3 2017 | $364,000 | +19.3% | 14,537 | +22.4% | 0.02% | +90.0% |
| Q2 2015 | $305,000 | +52.5% | 11,872 | +128.7% | 0.01% | +42.9% |
| Q4 2014 | $200,000 | – | 5,191 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Omega Fund Management, LLC | 2,600,410 | $33,805,000 | 33.22% |
| Abingworth LLP | 1,041,131 | $13,535,000 | 8.41% |
| Roumell Asset Management, LLC | 197,347 | $2,566,000 | 5.65% |
| Trellus Management Company, LLC | 89,700 | $1,166,000 | 2.12% |
| Prosight Management, LP | 148,682 | $1,933,000 | 1.21% |
| Broadfin Capital, LLC | 477,607 | $6,209,000 | 0.97% |
| HIGHLAND CAPITAL MANAGEMENT LP | 959,278 | $12,471,000 | 0.64% |
| ARMISTICE CAPITAL, LLC | 580,000 | $7,540,000 | 0.58% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,500 | $1,346,000 | 0.52% |
| Opus Point Partners Management, LLC | 20,000 | $260,000 | 0.51% |